Evaluation of NovoRapid infusion as a treatment option in the management of diabetic ketoacidosis

Raylene Kwok, Shoshana Sztal-Mazer, Ria E. Hopkins, Susan G. Poole, Louise Grannell, John Coutsouvelis, Duncan J. Topliss

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


This study evaluates the clinical efficacy and safety of NovoRapid (insulin aspart) compared to Actrapid™ (human neutral insulin) for diabetic ketoacidosis (DKA). In this retrospective study involving 40 patients, no statistically significant differences were observed between biochemical variables, infusion duration or complications in patients treated with insulin aspart or human neutral insulin. These results support the use of insulin aspart as an effective and safe alternative to human neutral insulin in DKA.

Original languageEnglish
Pages (from-to)1317-1320
Number of pages4
JournalInternal Medicine Journal
Issue number11
Publication statusPublished - Nov 2017


  • diabetic ketoacidosis
  • infusions, intravenous
  • insulin
  • insulin aspart
  • insulin, short acting

Cite this